生物技术

The AI Revolution in Biotechnology: A New Turning Point in Drug Development and Precision Medicine by 2025

Editor
8 分钟阅读

As of the end of 2025, the biotechnology industry is experiencing an unprecedented wave of change through its integration with artificial intelligence. The global AI biotech market size is expected to grow from $92 billion in 2024 to $124 billion in 2025, a sharp increase of 34.8%, paving the way for innovative breakthroughs in traditional drug development and precision medicine. Particularly, the practical application of technologies such as large language models (LLMs) and deep learning for protein structure prediction, molecular design, and clinical trial optimization is becoming a reality, potentially reducing the traditional drug development timeline from 10-15 years to 5-7 years.

The AI Revolution in Biotechnology: A New Turning Point in Drug Development and Precision Medicine by 2025

At the heart of this transformation are AI models like Google DeepMind’s AlphaFold 3.0 and Meta’s ESM-3. Since its release in the first half of 2025, AlphaFold 3.0 has predicted over 200 million protein structures with 99.5% accuracy, demonstrating a time-saving effect of over 70% in the drug target discovery process compared to traditional methods. Meanwhile, Meta’s ESM-3 has shown the capability to simultaneously predict structure and function from protein sequences, achieving a success rate of over 95% in antibody design. The commercialization of these AI tools is fundamentally reshaping R&D investment strategies in the global pharmaceutical industry, with the average AI investment share of the top 20 pharmaceutical companies reaching 28% of their total R&D budget by 2025.

South Korea’s biotech ecosystem is also rapidly growing in line with these global trends. According to the Korea Biotechnology Industry Organization, the domestic AI biotech market size increased by 48.3% from 890 billion won in 2024 to 1.32 trillion won in 2025, significantly surpassing the global average growth rate. Notably, Samsung Biologics (Incheon, Gyeonggi-do) achieved a 15% improvement in production yield by introducing an AI-based biopharmaceutical production optimization system in the second half of 2025, while Celltrion (Incheon) announced that it had reduced the development period of biosimilars from five years to three years by establishing an AI-driven development platform. These achievements suggest that South Korea is solidifying its position as a global biotech manufacturing hub while emerging as a leader in next-generation biotech innovation based on AI technology.

AI Innovation in Drug Development Paradigm

The most significant change in the traditional drug development process is occurring in the early target discovery and lead compound optimization stages. Previously, the mainstream approach involved random screening of thousands of compounds, but now the paradigm is shifting to AI algorithms learning complex correlations between molecular structures and biological activity to predict optimal candidate substances. UK-based Exscientia announced that its AI-designed drug DSP-1181 showed 40% higher efficacy compared to existing treatments in Phase 2 clinical trials in 2025, demonstrating the tangible outcomes of AI drug development. This drug is the first AI-designed case to enter late-stage clinical trials, with the development period shortened from eight years to four and a half years.

American pharmaceutical giants are also expanding large-scale investments in AI drug development. Johnson & Johnson (New Jersey) invested $1.5 billion in 2025 in its dedicated AI drug development organization, ‘J&J Innovation Labs,’ to accelerate the development of next-generation immuno-oncology and rare disease treatments. Pfizer (New York) has built a quantum computing-based molecular simulation platform through a partnership with IBM. This new platform can calculate molecular interactions 1,000 times faster than existing supercomputers, enabling the development of next-generation therapies targeting complex protein-protein interactions. Due to such technological advancements, the number of AI-designed drugs approved by the FDA reached 23 in 2025, nearly tripling from eight in 2024.

The use of AI in clinical trial design and patient recruitment is also rapidly increasing. Swiss-based Roche (Basel) introduced an AI-based patient screening system in 2025, reducing the average recruitment period for clinical trial participants from six months to 2.5 months and improving trial success rates from 78% to 89%. This system comprehensively analyzes electronic health records (EHR), genomic data, and lifestyle information to pre-identify patient groups most suitable for specific treatments. Additionally, Novartis (Basel, Switzerland) commercialized a system that uses digital biomarkers to collect and analyze data from patients’ smartphones and wearable devices in real-time, monitoring drug responses 24/7 during clinical trials. These innovative approaches have simultaneously improved the accuracy and efficiency of clinical trials, with the global clinical trial market size growing from $48 billion in 2024 to $59 billion in 2025, a 22.9% increase.

A particularly noteworthy case is AbbVie’s (Illinois) AI-based immuno-oncology development project. In early 2025, AbbVie entered into a strategic partnership with Google Cloud to build an AI platform that analyzes the tumor immune environment in real-time and proposes personalized cancer treatment strategies. This platform analyzes over 50,000 immune cell profiles from a patient’s tumor tissue sample to suggest the optimal combination of immuno-oncology drugs, showing a 50% higher response rate compared to existing standard treatments in early clinical trials. Based on these achievements, AbbVie’s market capitalization surpassed $320 billion by the end of 2025, firmly maintaining its position as one of the top three companies in the global pharmaceutical industry.

New Horizons in Precision Medicine and Personalized Treatment

The advancement of AI technology is also driving revolutionary changes in the field of precision medicine. As of 2025, the global collection of genomic data has surpassed one billion, leading to the full-scale development of personalized treatment strategies based on this data. Genomics England completed a database of five million genomes in 2025, increasing the accuracy of rare disease diagnosis to 95%, while the US NIH’s All of Us program secured genomic data from two million people of diverse ethnicities, successfully analyzing drug response differences by race. AI models trained on these large datasets can now propose optimal treatment strategies by comprehensively considering individual patients’ genetic variations, lifestyle, and environmental factors.

In South Korea, the use of AI in the precision medicine field is rapidly expanding. Seoul National University Hospital and Samsung Medical Center jointly established a ‘Korean Personalized Precision Medicine Platform’ in 2025, developing AI models that analyze the unique genetic variations and disease susceptibilities of Koreans. This platform integrates and analyzes the genomes, proteomes, and metabolomes of 500,000 Koreans to predict the risk of major diseases such as diabetes, hypertension, and cancer with 95% accuracy and suggests optimal drugs and dosages for individuals. Particularly for gastric cancer, which has a high prevalence among Koreans, early diagnosis using this AI model has significantly improved the five-year survival rate from 75% to 92%.

The global precision medicine market is witnessing fierce competition between US and Chinese companies. Illumina (California) succeeded in lowering the cost of next-generation sequencing (NGS) to below $100 per genome in 2025, leading the popularization of genomic analysis, while China’s BGI Genomics (Shenzhen) established the largest genomic database in Asia to develop Asia-specific precision medicine solutions. Notably, BGI achieved a 99.9% accuracy rate for its AI-based prenatal diagnostic kits in the second half of 2025, capturing a 45% global market share and recording an annual revenue of $3.8 billion, experiencing rapid growth.

In the precision medicine field, immunotherapy and cell therapy are particularly noteworthy areas. In the case of CAR-T cell therapy, AI-driven personalized design has significantly improved treatment success rates. Novartis, the developer of Kymriah, enabled the design of optimized CAR-T cells for individual patients within 48 hours using an AI-based CAR-T design platform in 2025, improving the treatment response rate from 60% to 85%. Additionally, China’s Legend Biotech achieved a complete remission rate of 95% for multiple myeloma patients with its AI-optimized CAR-T therapy, gaining global attention. Based on these achievements, the global cell therapy market size grew from $8.9 billion in 2024 to $12.5 billion in 2025, a 40.4% increase.

Meanwhile, the combination of liquid biopsy technology and AI is also significantly contributing to the advancement of precision medicine. Guardant Health (California) commercialized a technology in 2025 that can detect over 50 types of cancer with 95% accuracy through an AI-based blood test, achieving an annual revenue of $1.5 billion. This technology analyzes subtle changes in circulating tumor DNA (ctDNA) in the blood to predict not only the presence of cancer but also its location, stage, and treatment response. Domestically, Macrogen and Theragen Etex are also accelerating the development of AI-based liquid biopsy technology, with the domestic liquid biopsy market size estimated to reach 280 billion won by the end of 2025.

The AI revolution in the biotechnology industry in 2025 is fundamentally changing the medical paradigm beyond mere technological progress. The significant reduction in drug development timelines, the practical application of precision medicine, and the generalization of personalized treatment provide better treatment opportunities for patients while greatly improving the profitability of the pharmaceutical industry. With the global AI biotech market expected to sustain high growth at an average annual rate of 32% over the next five years, the technological competitiveness and market responsiveness of major countries, including South Korea, will be key factors determining their status in the future biotech ecosystem. Particularly, the harmonious development of AI technology, data infrastructure, and regulatory innovation is analyzed to be crucial for the success of the next-generation biotech revolution, which investors and industry stakeholders should closely monitor.

This analysis is based on publicly available market data and industry reports and is not intended as investment advice or a recommendation for specific companies. Please seek expert advice when making investment decisions.

#Samsung Biologics #Celltrion #Johnson & Johnson #Roche Holding #Novartis #Pfizer #AbbVie

Editor

Leave a Comment

Related Articles

生物科技产业的AI革命:从2026年药物发现到个性化治疗

AI可用于药物开发多个阶段的数据生成和分析。FDA与EMA的药物开发良好AI实践原则要求明确使用情境,并根据风险开展验证和性能评估。这些原则并未认定AI能将所有药物开发周期平均缩短70%,也未认定2026年AI生物科技市场达到1200亿美元。市场规模数据应附有明确界定范围和方法的来源。 目前,AI在生物科技产业中的应用主要分为三个领域。首先是加速药物发现和开发,AI应用于从分子设计到临床试验优化的全过程。其次是个性化治疗的开发,基于基因分析和患者数据的精准医学正在成为现实。第三是生物制造过程的优化,通过AI实现质量管理和产量提升。这些变化直接影响了生物科技企业的研发投资模式,截至2026年上半年,主要生物科技企业的AI相关研发投资同比平均增长了85%。 在药物发现领域,AI的影响力尤为显著。自英国DeepMind开发的AlphaFold以来,蛋白质结构预测技术彻底改变了药物设计的范式。截至2026年1月,AlphaFold数据库中已注册超过2亿个蛋白质结构,利用这些数据挖掘药物候选物的数量较2025年增长了120%。美国加州的Scripps Research宣布,利用AI比传统方法提前6个月,在18个月内发现了针对COVID-19变异病毒的新治疗候选物。 AI基础药物开发的当前趋势和成就 目前,全球制药公司正在大幅增加对AI基础药物开发平台的投资。瑞士的罗氏(Roche)宣布将在2025年底前向AI药物发现部门投资15亿美元,相当于其整体研发预算的12%。美国的强生(J&J)也计划从2026年起三年内总计投入25亿美元用于AI基础新药开发。这些大规模投资的背景是AI确实显示出了可见的成果。 具体的成就指标显示,利用AI挖掘药物候选物的成功率从传统方法的12%提高到28%,翻了一倍多。此外,从临床前阶段进入临床一期所需的时间也从平均4.2年缩短到2.8年。美国马萨诸塞州的Moderna宣布,通过AI基础的mRNA疫苗开发平台,将新型传染病疫苗的开发时间从传统的10-15年缩短到6个月以内。这被认为是AI在疫情情况下潜力的明确展示。 韩国的生物科技产业也积极参与这场AI革命。总部位于京畿道松岛的三星生物制剂宣布,自2025年下半年起引入AI基础生物药品生产优化系统,将生产产量平均提高了15%。此外,位于仁川的Celltrion通过建立AI基础的生物仿制药开发平台,将开发时间从原来的7-8年缩短到4-5年。这些成就对于韩国生物科技公司在全球市场上获得竞争力起到了重要作用。 特别值得注意的是AI基础生物科技初创公司的增长势头。截至2026年第一季度,全球AI-生物初创公司的风险投资总额达到87亿美元,较2025年同期增长了65%。其中约40%投资于药物发现平台,25%投资于个性化治疗开发,其余35%投资于诊断和生物制造优化。在韩国,KAIST出身的研究团队创立的AI新药开发初创公司接连在B轮融资中获得大规模投资,备受关注。 个性化治疗和精准医学的现实化 根据美国国家癌症研究所的说明,生物标志物检测可能有助于依据患者癌症的特征选择治疗,但其应用和结果会因癌种、生物标志物和疗法而异,精准医疗尚未成为大多数患者的常规治疗。因此,不能笼统声称基于AI基因分析的个性化治疗比标准治疗使各种癌症的五年生存率平均提高23%。 这些成就的核心在于AI的模式识别能力。目前,AI系统可以同时分析患者的基因信息、生活习惯数据、临床记录等数十万个变量,提出最佳治疗方案。总部位于瑞士巴塞尔的诺华(Novartis)宣布,利用AI在CAR-T细胞治疗开发中,将患者个性化制造时间从原来的4-6周缩短到2-3周。这对提高患者生存率产生了直接影响。 在精准医学领域,韩国企业的成就也值得关注。总部位于首尔江南区的Macrogen通过AI基础的基因组分析平台开发了亚洲人特化疾病预测模型。该模型在糖尿病、高血压、痴呆等主要慢性疾病方面较西方人模型提高了15-20%的预测准确度。此外,通过与分当首尔大学医院的合作,开发了反映韩国人基因特性的个性化抗癌药选择算法,正在临床应用中。 个性化治疗的市场规模也在迅速扩大。全球精准医学市场从2025年的950亿美元增长到2026年的1180亿美元,增长了24.2%,其中AI基础解决方案占比达到35%。特别是亚太地区的增长率尤为显著,以韩国、日本、中国为中心的该地区精准医学市场在2026年达到280亿美元,较前一年增长了42%。这被分析为亚洲各国政府的精准医学培育政策与高水平IT基础设施相结合的结果。 然而,个性化治疗的普及仍面临挑战。最大的问题是高昂的治疗费用,目前AI基础个性化治疗的费用是标准治疗的3-5倍。此外,数据隐私和安全问题、医务人员的AI应用能力不足等也被指出是需要解决的课题。为应对这些问题,各国政府和医疗机构正在着手相关制度的整备和人才培养。韩国政府也宣布从2026年起为期五年、规模2000亿韩元的精准医学专业人才培养投资计划。 在生物制造领域,AI的影响力也在扩大。传统上,生物药品制造包括复杂的生物过程,质量管理要求严格。然而,通过引入AI基础的实时监控和预测系统,制造过程的稳定性和效率得到了显著提高。总部位于美国伊利诺伊州的艾伯维(AbbVie)宣布,通过AI基础的制造优化系统,将生物药品生产产量平均提高了18%,不良率减少了60%。 这些成就对生物药品的供应稳定性和价格竞争力具有重要意义。特别是在新冠疫情后,生物药品供应链的重要性凸显,AI基础的制造优化被视为国家层面的战略课题。韩国的三星生物制剂也在松岛第三工厂建立了AI基础的智能制造系统,并于2025年下半年开始正式运营。该系统通过实时质量监控预测制造过程中的变量并自动调整,以确保产品质量的一致性。 目前生物科技产业的AI引入有几个主要动力。首先是计算性能的急剧提升。基于GPU的高性能计算的发展使复杂的分子模拟和大规模数据分析以现实的成本成为可能。其次是生物数据的爆炸性增长。随着基因组分析成本的持续下降,积累的生物数据量呈指数级增长,为AI模型的学习提供了原料。第三是监管环境的改善。包括FDA在内的各国监管机构正在整理AI基础医疗设备和治疗方法的批准指南,使商业化路径更加明确。 在投资方面,生物科技AI领域也显示出活跃的动向。截至2026年第一季度,全球生物科技领域的风险投资中,AI相关投资占比为32%,较2020年的8%增长了4倍。特别是大型制药公司对AI生物科技初创公司的并购活动日益活跃。2025年一年内,规模超过10亿美元的AI生物科技并购达成了12起,总交易规模达到180亿美元。这表明生物科技行业将AI视为核心竞争力而不仅仅是工具。 然而,在AI与生物科技的融合过程中出现的课题也不容忽视。最重要的问题是数据质量和标准化。AI模型的性能很大程度上取决于学习数据的质量,而医疗数据可能因收集机构和方法的不同而存在偏差。此外,种族、性别、年龄等引起的数据偏向问题也需解决。目前大多数医疗AI模型基于西方人数据开发,应用于亚洲人时准确性可能下降。为应对这一问题,各国正在构建反映本国国民特性的医疗数据库。…

生物技术革命的新转折点:2026年AI-生物融合与个性化医疗的快速增长

到2026年,生物技术行业通过与人工智能的融合,迎来了前所未有的变革。个性化医疗和基因治疗领域的突破性进展不断涌现,预计全球生物技术市场规模将突破1.2万亿美元。

生物技术产业的AI融合与个性化医疗的未来:2026年市场分析

人工智能与生物技术的融合正在开启个性化医疗的新时代。截至2026年,全球生物技术市场已增长至1.2万亿美元,基于AI的新药开发和基因治疗领域的创新变革正在加速。